OncoSynergy improves outcomes for patients with unmet needs in oncology with resistance mechanism inhibitors.
OncoSynergy has raised $6.6M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2026.
OncoSynergy's investors include Connecticut Innovations, Korea Information & Communication Co., NLabs.
OncoSynergy is headquartered in Stamford, United States.
OncoSynergy improves outcomes for patients with unmet needs in oncology with resistance mechanism inhibitors.
OncoSynergy is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OncoSynergy — Funding & Investors." VCBacked, May 26, 2026, https://www.vcbacked.co/company/oncosynergy. Accessed July 19, 2026.
VCBacked. (2026). OncoSynergy — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/oncosynergy
{{cite web |title=OncoSynergy — Funding & Investors |url=https://www.vcbacked.co/company/oncosynergy |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated